Hesperetin Activates the Notch1 Signaling Cascade, Causes Apoptosis, and Induces Cellular Differentiation in Anaplastic Thyroid Cancer

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2014 Jan 15

PMID 24419754

Citations 25

Authors

Priyesh N Patel

Xiao-Min Yu

Renata Jaskula-Sztul

Herbert Chen

Affiliations

Soon will be listed here.

Abstract

Background: Anaplastic thyroid cancer (ATC) is characterized by very aggressive growth with undifferentiated features. Recently, it has been reported that the Notch1 signaling pathway, which affects thyrocyte proliferation and differentiation, is inactivated in ATC. However, it remains largely unknown whether using Notch1 activating compounds can be an effective therapeutic strategy in ATC. Therefore, in this study, we aimed to evaluate the drug effects of a potential Notch activator hesperetin on ATC cell.

Methods: A unique ATC cell line HTh7 was used to evaluate the drug effects of hesperetin. The Notch1 activating function and cell proliferation were evaluated. The mechanism of growth regulation was investigated by the detection of apoptotic markers. The expression levels of thyrocyte-specific genes were quantified for ATC redifferentiation.

Results: Upregulated expression of Notch1 and its downstream effectors hairy and enhancer of split 1 (Hes1) and Hes1 related with YRPW motif was observed in hesperetin-treated ATC cells. The enhanced luciferase signal also confirmed the functional activity of hesperetin-induced Notch1 signaling. Hesperetin led to a time- and dose-dependent decrease in ATC cell proliferation. The cell-growth inhibition was mainly caused by apoptosis as evidenced by increased levels of cleaved poly ADP ribose polymerase and cleaved caspase-3 as well as decreased survivin. Additionally, hesperetin induced the expression levels of thyrocyte-specific genes including thyroid transcription factor 1 (TTF1), TTF2, paired box gene 8, thyroid stimulating hormone receptor, and sodium/iodide symporter.

Conclusions: Hesperetin activates the Notch1 signaling cascade and suppresses ATC cell proliferation mainly via apoptosis. Hesperetin also induces cell redifferentiation of ATC, which could be useful clinically.

Citing Articles

Promising Approaches in Plant-Based Therapies for Thyroid Cancer: An Overview of In Vitro, In Vivo, and Clinical Trial Studies.

Kaczmarzyk I, Nowak-Perlak M, Wozniak M Int J Mol Sci. 2024; 25(8).

PMID: 38674046 PMC: 11050626. DOI: 10.3390/ijms25084463.

Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells.

Qi Y, Li M, Li S, Zeng D, Xiao Y, Li J Cell Death Discov. 2023; 9(1):204.

PMID: 37391408 PMC: 10313677. DOI: 10.1038/s41420-023-01487-x.

Exploring cell competition for the prevention and therapy of esophageal squamous cell carcinoma.

Knapp K, Verchio V, Coburn-Flynn O, Li Y, Xiong Z, Morrison J Biochem Pharmacol. 2023; 214:115639.

PMID: 37290594 PMC: 10528900. DOI: 10.1016/j.bcp.2023.115639.

Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions.

Hassan A, El-Kalaawy A, Abd El-Twab S, Alblihed M, Ahmed O Life (Basel). 2023; 13(4).

PMID: 37109513 PMC: 10146346. DOI: 10.3390/life13040984.

Modulation of Notch Signaling Pathway by Bioactive Dietary Agents.

Kiesel V, Stan S Int J Mol Sci. 2022; 23(7).

PMID: 35408894 PMC: 8998406. DOI: 10.3390/ijms23073532.

References

Kunnimalaiyaan M, Chen H . Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 2007; 12(5):535-42. DOI: 10.1634/theoncologist.12-5-535. View

Lin J, Wu M, Wang W, Yen C, Chiou T, Liu J . All-trans retinoid acid increases Notch1 transcript expression in acute promyelocytic leukemia. Adv Ther. 2004; 20(6):337-43. DOI: 10.1007/BF02849800. View

So F, Guthrie N, Chambers A, Moussa M, Carroll K . Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer. 1996; 26(2):167-81. DOI: 10.1080/01635589609514473. View

Kogai T, Taki K, Brent G . Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006; 13(3):797-826. DOI: 10.1677/erc.1.01143. View

Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J . Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun. 1997; 240(3):832-8. DOI: 10.1006/bbrc.1997.7715. View

Li F, Ye L, Lin S, Leung L . Dietary flavones and flavonones display differential effects on aromatase (CYP19) transcription in the breast cancer cells MCF-7. Mol Cell Endocrinol. 2011; 344(1-2):51-8. DOI: 10.1016/j.mce.2011.06.024. View

Adler J, Hottinger D, Kunnimalaiyaan M, Chen H . Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol. 2008; 16(2):481-6. PMC: 2740795. DOI: 10.1245/s10434-008-0194-6. View

Ohmori M, Endo T, HARII N, Onaya T . A novel thyroid transcription factor is essential for thyrotropin-induced up-regulation of Na+/I- symporter gene expression. Mol Endocrinol. 1998; 12(5):727-36. DOI: 10.1210/mend.12.5.0101. View

Artavanis-Tsakonas S, Rand M, Lake R . Notch signaling: cell fate control and signal integration in development. Science. 1999; 284(5415):770-6. DOI: 10.1126/science.284.5415.770. View

10.

Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke W . Retinoic acid for redifferentiation of thyroid cancer--does it hold its promise?. Eur J Endocrinol. 2003; 148(4):395-402. DOI: 10.1530/eje.0.1480395. View

11.

Xiao X, Ning L, Chen H . Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther. 2009; 8(2):350-6. PMC: 2673961. DOI: 10.1158/1535-7163.MCT-08-0585. View

12.

Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T . IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998; 58(23):5315-20. View

13.

Kunnimalaiyaan M, Yan S, Wong F, Zhang Y, Chen H . Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery. 2005; 138(6):1137-42. DOI: 10.1016/j.surg.2005.05.027. View

14.

Wang Z, Liu Y, Cui Y . Pathways to caspase activation. Cell Biol Int. 2005; 29(7):489-96. DOI: 10.1016/j.cellbi.2005.04.001. View

15.

Cornett W, Sharma A, Day T, Richardson M, Hoda R, van Heerden J . Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep. 2007; 9(2):152-8. DOI: 10.1007/s11912-007-0014-3. View

16.

Katoh M, Katoh M . Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol. 2007; 31(2):461-6. View

17.

Lentini A, Forni C, Provenzano B, Beninati S . Enhancement of transglutaminase activity and polyamine depletion in B16-F10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential. Amino Acids. 2006; 32(1):95-100. DOI: 10.1007/s00726-006-0304-3. View

18.

Castella P, Sawai S, Nakao K, Wagner J, Caudy M . HES-1 repression of differentiation and proliferation in PC12 cells: role for the helix 3-helix 4 domain in transcription repression. Mol Cell Biol. 2000; 20(16):6170-83. PMC: 86092. DOI: 10.1128/MCB.20.16.6170-6183.2000. View

19.

Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G . Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 2008; 33(4):341-57. View

20.

Nagaiah G, Hossain A, Mooney C, Parmentier J, Remick S . Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011; 2011:542358. PMC: 3136148. DOI: 10.1155/2011/542358. View